T-MAXIMUM PHARMACEUTICAL Unveils CAR-T Breakthrough for Solid Tumours

T-MAXIMUM PHARMACEUTICAL Unveils CAR-T Breakthrough for Solid Tumours

By, Admin 10 August 2024

Overview

T-MAXIMUM PHARMACEUTICAL, a biotechnology company specialising in universal cell-based therapies, has received international praise for its pioneering work in allogeneic CAR-T cell therapy.

About MT027

  • MT027, the lead product in T-MAXIMUM’s pipeline, is an allogeneic CAR-T therapy modified using CRISPR/Cas9 technology to target the B7-H3 tumour antigen in recurrent glioblastoma and other solid tumours. 
  • Early studies have shown it to be both effective and safe. 
  • MT027 could potentially treat various late-stage solid tumours, offering hope to patients with aggressive cancers.

Preparation for Registrering MT027

  • T-MAXIMUM is preparing MT027 for registration and clinical trials in the United States, with manufacturing already finalised and partnerships established with third-party manufacturers in China and the United States. 
  • The product has received Orphan Drug Designation from the US FDA, which could expedite its approval process. 
  • In addition to MT027, the company is developing two other allogeneic CAR-T therapies: MT026, targeting IL13Rα2 for solid tumours, and MT020, aimed at treating B-cell related autoimmune diseases.

For Novel Allogeneic CAR-T Therapies

  • T-MAXIMUM, has also announced the development of next-generation allogeneic CAR-T therapies for solid tumours, which will involve more advanced T-cell engineering. 
  • The company is exploring strategies to combine CAR-T cells with other treatments to improve disease control in advanced solid tumours, ultimately aiming to transform these tumours into manageable chronic conditions.

About Traditional CAR-T Cell Therapies

  • Traditional CAR-T cell therapies typically use a patient’s own cells, which can be time-consuming and expensive to produce. 
  • This method also carries risks, including the potential for manufacturing failures and insufficient T cells in patients who have undergone extensive treatments. 
  • In contrast, allogeneic CAR-T therapies use T cells from healthy donors, which are more abundant and functional. 
  • This approach allows for the creation of ""off-the-shelf"" products, offering a more scalable and accessible treatment option.

About Solid Tumours

  • Solid tumours, which make up about 90% of all cancers, represent a significant unmet medical need, especially in their late stages. 
  • While cell therapies have shown success in treating blood cancers, progress in solid tumours has been limited. 
  • T-MAXIMUM’s allogeneic CAR-T therapies are designed to enhance effectiveness and overcome rejection issues, making them a promising tool against solid tumours like glioblastoma. 
  • Initial clinical trials have shown encouraging results, with the therapy demonstrating a favourable safety profile in over 50 patients.

Trial Presentation at ASCO

  • The company recently presented a trial at the 2024 American Society of Clinical Oncology (ASCO) Breakthrough Summit, focusing on the use of B7H3-specific allogeneic CAR-T cells for treating recurrent high-grade glioma. 
  • This study, involving intrathecal or intracerebroventricular administration, was awarded one of only 40 Abstract Awards at the conference.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!